Get started
Work

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

Year: 2020
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.annonc.2020.08.1575
Authors: G.J. Riely, J.W. Neal, D.R. Camidge, A. Spira, Z. Piotrowska, L. Horn, D.B. Costa, A. Tsao, J. Patel, S. Gadgeel, L. Bazhenova, V.W. Zhu, H. West, T. Mekhail, R. Gentzler, D. Nguyen, V. Bunn, S. Jin, Z. Feng, P.A. Jänne
Institutions: Memorial Sloan Kettering Cancer Center, Stanford Cancer Institute, Stanford University, University of Colorado Cancer Center, Virginia Cancer Specialists, Massachusetts General Hospital, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Michigan, UC San Diego Health System, Moores Cancer Center, University of California, Irvine, City of Hope, AdventHealth Orlando, University of Virginia Cancer Center, Takeda Oncology (United States), Dana-Farber Cancer Institute
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3089112132
FWCI: 1.734
Cites:
Cited by: 18
Related to: 10